124 related articles for article (PubMed ID: 24859989)
1. The social network of PELP1 and its implications in breast and prostate cancers.
Gonugunta VK; Miao L; Sareddy GR; Ravindranathan P; Vadlamudi R; Raj GV
Endocr Relat Cancer; 2014 Aug; 21(4):T79-86. PubMed ID: 24859989
[TBL] [Abstract][Full Text] [Related]
2. PELP1: Structure, biological function and clinical significance.
Sareddy GR; Vadlamudi RK
Gene; 2016 Jul; 585(1):128-134. PubMed ID: 26997260
[TBL] [Abstract][Full Text] [Related]
3. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.
Nair SS; Guo Z; Mueller JM; Koochekpour S; Qiu Y; Tekmal RR; Schüle R; Kung HJ; Kumar R; Vadlamudi RK
Mol Endocrinol; 2007 Mar; 21(3):613-24. PubMed ID: 17192406
[TBL] [Abstract][Full Text] [Related]
4. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR.
Vadlamudi RK; Kumar R
Nucl Recept Signal; 2007 May; 5():e004. PubMed ID: 17525794
[TBL] [Abstract][Full Text] [Related]
5. Regulation of rDNA transcription by proto-oncogene PELP1.
Gonugunta VK; Nair BC; Rajhans R; Sareddy GR; Nair SS; Vadlamudi RK
PLoS One; 2011; 6(6):e21095. PubMed ID: 21695158
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Rajhans R; Nair S; Holden AH; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2007 Jun; 67(11):5505-12. PubMed ID: 17545633
[TBL] [Abstract][Full Text] [Related]
7. Estradiol-Induced MMP-9 Expression via PELP1-Mediated Membrane-Initiated Signaling in ERα-Positive Breast Cancer Cells.
Pan Y; Wang X; Zhang Y; Qiao J; Sasano H; McNamara K; Zhao B; Zhang D; Fan Y; Liu L; Jia X; Liu M; Song S; Wang L
Horm Cancer; 2020 Apr; 11(2):87-96. PubMed ID: 32037484
[TBL] [Abstract][Full Text] [Related]
8. PELP1: a key mediator of oestrogen signalling and actions in the brain.
Thakkar R; Sareddy GR; Zhang Q; Wang R; Vadlamudi RK; Brann D
J Neuroendocrinol; 2018 Feb; 30(2):. PubMed ID: 28485080
[TBL] [Abstract][Full Text] [Related]
9. Emerging significance of ER-coregulator PELP1/MNAR in cancer.
Nair S; Vadlamudi RK
Histol Histopathol; 2007 Jan; 22(1):91-6. PubMed ID: 17128415
[TBL] [Abstract][Full Text] [Related]
10. PELP1: A novel therapeutic target for hormonal cancers.
Chakravarty D; Tekmal RR; Vadlamudi RK
IUBMB Life; 2010 Mar; 62(3):162-9. PubMed ID: 20014005
[TBL] [Abstract][Full Text] [Related]
11. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.
Chakravarty D; Nair SS; Santhamma B; Nair BC; Wang L; Bandyopadhyay A; Agyin JK; Brann D; Sun LZ; Yeh IT; Lee FY; Tekmal RR; Kumar R; Vadlamudi RK
Cancer Res; 2010 May; 70(10):4092-101. PubMed ID: 20460518
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
13. Functional implications of altered subcellular localization of PELP1 in breast cancer cells.
Vadlamudi RK; Manavathi B; Balasenthil S; Nair SS; Yang Z; Sahin AA; Kumar R
Cancer Res; 2005 Sep; 65(17):7724-32. PubMed ID: 16140940
[TBL] [Abstract][Full Text] [Related]
14. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA; Viswanadhapalli S; Mann M; Chakravarty D; Krishnan S; Liu Z; Liu J; Pratap UP; Ebrahimi B; Sanchez JR; Li X; Ma S; Park BH; Santhamma B; Chen Y; Lai Z; Raj GV; Yuan Y; Zhou D; Sareddy GR; Tekmal RR; McHardy S; Huang TH; Rao MK; Vankayalapati H; Vadlamudi RK
Cancer Res; 2022 Oct; 82(20):3830-3844. PubMed ID: 35950923
[TBL] [Abstract][Full Text] [Related]
15. Cryo-EM reveals the architecture of the PELP1-WDR18 molecular scaffold.
Gordon J; Chapus FL; Viverette EG; Williams JG; Deterding LJ; Krahn JM; Borgnia MJ; Rodriguez J; Warren AJ; Stanley RE
Nat Commun; 2022 Nov; 13(1):6783. PubMed ID: 36351913
[TBL] [Abstract][Full Text] [Related]
16. PELP1 oncogenic functions involve alternative splicing via PRMT6.
Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R
Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.
Wang X; Tsang JYS; Lee MA; Ni YB; Tong JH; Chan SK; Cheung SY; To KF; Tse GM
Cancer Res Treat; 2019 Apr; 51(2):706-717. PubMed ID: 30134648
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages.
Girard BJ; Knutson TP; Kuker B; McDowell L; Schwertfeger KL; Ostrander JH
J Biol Chem; 2017 Jan; 292(1):339-350. PubMed ID: 27881676
[TBL] [Abstract][Full Text] [Related]
19. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.
Roy SS; Gonugunta VK; Bandyopadhyay A; Rao MK; Goodall GJ; Sun LZ; Tekmal RR; Vadlamudi RK
Oncogene; 2014 Jul; 33(28):3707-16. PubMed ID: 23975430
[TBL] [Abstract][Full Text] [Related]
20. Cancer Stem Cell Phenotypes in ER
Truong TH; Hu H; Temiz NA; Hagen KM; Girard BJ; Brady NJ; Schwertfeger KL; Lange CA; Ostrander JH
Mol Cancer Res; 2018 Apr; 16(4):707-719. PubMed ID: 29348189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
